AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • February 28th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT CREDIT AGREEMENT (this “Amendment”), dated as of December 22, 2010, is made by and among GILEAD SCIENCES, INC., a Delaware corporation (the “Parent”), GILEAD BIOPHARMACEUTICS IRELAND CORPORATION, an Irish company (“Gilead Ireland”, Gilead Ireland together with the Parent are together referred to as the “Borrowers”, and each individually, as a “Borrower”), BANK OF AMERICA, N.A., a national banking association organized and existing under the laws of the United States (“Bank of America”), in its capacity as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), and each of the Lenders signatory hereto.
AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AGREEMENT AND LIMITED CONSENT AND WAIVERCredit Agreement • February 28th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED CREDIT AGREEMENT CREDIT AGREEMENT AND LIMITED CONSENT AND WAIVER (this “Amendment”), dated as of June 3, 2009, is made by and among GILEAD SCIENCES, INC., a Delaware corporation (the “Parent”), GILEAD BIOPHARMACEUTICS IRELAND CORPORATION, an Irish company (“Gilead Ireland”, Gilead Ireland together with the Parent are together referred to as the “Borrowers”, and each individually, as a “Borrower”), BANK OF AMERICA, N.A., a national banking association organized and existing under the laws of the United States (“Bank of America”), in its capacity as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), and each of the Lenders signatory hereto.
GILEAD SCIENCES LIMITED.-AMPAC FINE CHEMICALS LLC TENOFOVIR DISOPROXIL FUMARATE MANUFACTURING SUPPLY AGREEMENTSupply Agreement • February 28th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
THIS SUPPLY AGREEMENT (“Agreement”) is entered into as of November 3, 2010 (“Effective Date”), by and between Ampac Fine Chemicals LLC, a California limited liability company (“AFC”) having its principal place of business at Highway 50 & Hazel Avenue, Rancho Cordova, CA 95670, and a mailing address of P.O. Box 1718, Rancho Cordova, CA 95741, and Gilead Sciences Limited, an Irish limited company (“GSL”), having its principal place of business at Unit 13, Stillorgan Industrial Park, Blackrock, Co. Dublin, Ireland. AFC and GSL may be referred to individually as a “Party” and collectively as the “Parties” in this Agreement.
AGREEMENT AND PLAN OF MERGER dated as of December 19, 2010 by and among GILEAD SCIENCES, INC., ARROYO MERGER SUB, INC., ARRESTO BIOSCIENCES, INC. and HEALTHCARE VENTURES VIII, L.P., AS REPRESENTATIVEAgreement and Plan of Merger • February 28th, 2011 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of December 19, 2010, by and among Gilead Sciences, Inc., a Delaware corporation (“Parent”), Arroyo Merger Sub, Inc., a Delaware corporation (“AcquisitionCo”), Arresto Biosciences, Inc., a Delaware corporation (the “Company”) (AcquisitionCo and the Company being hereinafter sometimes referred to as the “Constituent Corporations”), and HealthCare Ventures VIII, L.P., a Delaware limited partnership, as representative of the Participants (as defined herein) (the “Representative”).
